Hormone Therapy-Chemo Combo Reduces Risk of Tumor Return in Highly Recurrent Breast Cancer, Phase 3 Trial Shows

Hormone Therapy-Chemo Combo Reduces Risk of Tumor Return in Highly Recurrent Breast Cancer, Phase 3 Trial Shows
Using chemotherapy in combination with hormone therapy in women with highly recurring forms of breast cancer reduces the likelihood of disease returning elsewhere in the body over nine years compared with hormone therapy alone, a Phase 3 trial shows. The research, “Clinical Outcomes by Chemotherapy Regimen in Patients with RS 26-100 in TAILORx,” was presented at the recent European Society for Medical Oncology (ESMO) 2019 Congress, in Barcelona, Spain, and also published in JAMA Oncology. TAILORx (NCT00310180) is a Phase 3 study sponsored by the National Cancer Institute (NCI) and led by the ECOG-ACRIN Cancer Research Group. It was designed to determine the best course of treatment for women with highly recurring forms of breast cancer, as defined by the Oncotype DX Breast Recurrence Score test. With more than 1,200 trial sites from six countries, TAILORx is the largest breast cancer treatment trial ever conducted. Oncotype DX, developed by Genomic Health, uses a tumor biopsy to examine the activity of 21 genes in a patient’s breast tumor, scoring it from 1 to 100 for the risk of cancer returning. It is intended for women newly diagnosed with breast cancer that's still at an early phase (I-IIIa), and is positive for estrogen receptors (ER-positive) but has no excess levels of the growth-promoting protein HER2 (HER2-negative). One of TAILORx's goals was to determine if adding chemotherapy to hormone (or endocrine) therapy would lower the likelihood of cancer recurrence in a sub-group of 1,389 women (median age of 56 years) with the most common form of early breast cancer — hormone receptor-positive (having estrogen and progesterone receptors) but HER2- and axillary node-negative (no cancer spreading to the axillary lymph nodes) — and deemed at h
Subscribe or to access all post and page content.